NEO
NeoGenomics, Inc.
Healthcare · Diagnostics & Research · NCM
$10.90
Data: 2026-05-28
✓ ETHICAL PASS

Unknown MOAT
HIGH
Data Confidence: 85.7%
Key Metrics

How this company measures up on the fundamentals that matter

Market Cap
$1.2B
Total market value of the company
Trailing P/E
N/A
Forward P/E
26.25
Based on estimated future earnings — lower means cheaper
Rev Growth
+11.1%
Year-over-year revenue change
Profit Margin
-13.3%
How much profit the company keeps from each dollar of revenue
ROE
-11.6%
Return on equity — how efficiently it uses shareholder money
Analyst Target
$14.00
+28% from current price — median analyst estimate
Recommendation
NONE
Consensus view from 9 analysts covering this stock
About NeoGenomics, Inc.

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

https://www.neogenomics.com

Country: United States Employees: 2,500 Industry: Diagnostics & Research
Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
0.0% N/A
Debt must be below 33% of total assets
Cash Ratio
0.0% N/A
Interest-bearing cash below 33% of assets
Receivables
0.0% N/A
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime
ACCUMULATION
Smart money appears to be building positions quietly
Sharpe Ratio
0.112
Positive but modest risk-adjusted returns
Kelly Fraction
-0.0080
No positive edge detected — the data suggests staying out
Calmar Ratio
-0.193
Drawdown risk outweighs the returns — higher risk profile
Annual Return
-14.2%
Historical annualised return based on price data
Max Drawdown
-74.0%
Largest peak-to-trough decline — the worst it has been
HMM State
SIDEWAYS
Price consolidating — no clear directional bias
Days in State
158
How long the current regime has persisted — longer means more stable
Market Data

Trading characteristics and market positioning

Beta
1.80
Significantly more volatile than the market
52W High
$13.74
21% below the year high
52W Low
$4.72
131% above the year low
Avg Volume
1,931,395
Average daily shares traded — higher means easier to buy and sell
Short Ratio
3.4
Days it would take all short sellers to cover — higher means more crowded
Short % Float
7.8%
Moderate short interest
Div Yield
N/A
Annual dividend as a percentage of the share price
EPS (TTM)
$-0.77
Earnings per share over the last 12 months
Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity
49.29
Heavy leverage — higher financial risk if revenues decline
Current Ratio
4.42
Strong balance sheet — comfortably covers short-term obligations
Quick Ratio
3.71
Like current ratio but excludes inventory — stricter test
Gross Margin
43.1%
Revenue left after cost of goods — higher means pricing power
Operating Margin
-9.3%
Profit from core operations before interest and tax
Free Cash Flow
$33M
Positive — the business generates more cash than it spends
Revenue (TTM)
$746M
Total revenue over the last 12 months
Net Income
$-99,208,000
Loss-making — spending exceeds revenue after all costs
Analyst Coverage
Analysts
9
Target High
$25.00
Target Median
$14.00
Target Low
$11.00
Political Trading Activity

Congressional trading disclosures involving this instrument

Date Politician Party Type Amount
2026-04-13 Josh Gottheimer Democrat Purchase 1K–15K
13 Apr2026 Josh Gottheimer Democrat buy 1K–15K
Source: Congressional disclosure filings. View all political trades at
Insider Intelligence
Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry (292 articles) Indicators Join Free →

Get our weekly market brief free.